Impact of Cilostazol on Restenosis After Percutaneous Coronary Balloon Angioplasty

• DOI: 10.1161/01.cir.100.1.21
• Publication Date: 2012-06-12T00:42:29Z
• Authors: Etsuo Tsuchikane; Atsunori Fukuhara; Tohru Kobayashi; Motohiro Kirino; Keita Yamasaki; Tomoko Kobayashi; Masahiro Izumi; Satoru Otsuji; Hitone Tateyama; Makoto Sakurai; Nobuhisa Awata
• Keywords: Cilostazol; Lumen (anatomy)

Background —Restenosis after percutaneous transluminal coronary (balloon) angioplasty (PTCA) remains a major drawback of the procedure. We previously reported that cilostazol, platelet aggregation inhibitor, inhibited intimal proliferation directional atherectomy and reduced restenosis rate in humans. The present study aimed to determine effect cilostazol on PTCA. Methods Results —Two hundred eleven patients with 273 lesions who underwent successful PTCA were randomly assigned (200 mg/d) group or aspirin (250 control group. Administration was initiated immediately continued for 3 months follow-up. Quantitative angiography performed before at Reference diameter, minimal lumen percent diameter stenosis (DS) measured by quantitative angiography. Angiographic defined as DS follow-up >50%. Eligible 94 123 99 129 baseline characteristics results showed no significant difference between 2 groups. However, significantly larger (1.65±0.55 vs 1.37±0.58 mm; P <0.0001) lower (34.1±17.8% 45.6±19.3%; Restenosis target lesion revascularization rates also (17.9% 39.5%; <0.001 11.4% 28.7%; <0.001). Conclusions —Cilostazol reduces